Complete Versus Culprit-Only Revascularization for ST-Segment Elevation Myocardial Infarction and Multivessel Disease

Sung Woo Kwon1, Sang Don Park2, Jeonggeun Moon3

  • 1Department of Cardiology, Inha University Hospital, Incheon, Korea.

Insights

Complete revascularization (CR) significantly reduced major adverse cardiovascular events (MACE) and cardiovascular death in ST-segment elevation myocardial infarction (STEMI) patients with multivessel disease (MVD). This approach using second-generation drug-eluting stents (DES) proved superior to culprit-only PCI over one year.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiovascular Research

Background:

  • ST-segment elevation myocardial infarction (STEMI) often presents with multivessel disease (MVD).
  • Optimal revascularization strategy in STEMI with MVD using second-generation drug-eluting stents (DES) remains debated.
  • Comparing complete revascularization (CR) versus culprit-only revascularization is crucial for patient outcomes.

Purpose of the Study:

  • To compare the clinical outcomes of CR versus culprit-only revascularization in STEMI patients with MVD.
  • To evaluate the efficacy of second-generation DES in different revascularization strategies.
  • To assess the impact on major adverse cardiovascular events (MACE) and cardiovascular death.

Main Methods:

  • A cohort study of 705 patients with STEMI and MVD from 2009-2014.
  • Patients underwent primary percutaneous coronary intervention (PCI) with second-generation DES.
  • CR involved PCI of all diseased vessels; culprit-only involved PCI of the infarct-related artery only.

Main Results:

  • Complete revascularization (CR) was performed in 59% of patients, while 41% received culprit-only PCI.
  • CR group showed significantly lower MACE rates (11.5% vs. 18.5%) compared to culprit-only PCI.
  • Cardiovascular death was also significantly lower in the CR group (7.2% vs. 12.9%).

Conclusions:

  • Complete revascularization (CR) is associated with improved outcomes in STEMI patients with MVD treated with second-generation DES.
  • CR significantly reduces MACE and cardiovascular death at one-year follow-up compared to culprit-only PCI.
  • These findings support CR as a preferred strategy in selected STEMI patients with MVD.
Abstract

Related Concept Videos

Freezing Point Depression and Boiling Point Elevation03:12

Freezing Point Depression and Boiling Point Elevation

Boiling Point Elevation
The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
40.1K
High-Performance Liquid Chromatography: Elution Process01:05

High-Performance Liquid Chromatography: Elution Process

In High-Performance Liquid Chromatography (HPLC), the elution process is critical to the separation of analytes and the quality of chromatographic results. Elution describes how compounds move through the column and separate based on their interactions with the mobile and stationary phases. This process determines the resolution, peak shape, and retention times in the chromatogram, which are essential for identifying and quantifying components in complex mixtures. Understanding the elution...
1.6K
Elevation of Intermediate Points on Vertical Curves01:20

Elevation of Intermediate Points on Vertical Curves

Vertical curves are essential in roadway design because they provide smooth transitions between varying roadway grades. Designing vertical curves involves calculating intermediate elevations and identifying the curve's highest or lowest point, which is essential for optimal roadway performance.Intermediate elevations on a vertical curve are determined using the tangent offset method. This method considers the initial elevation at the start of the curve, the grades, and the curve's geometry. The...
290
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
231
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
487